Novack Jeffrey Adam
Known title: Secretary and General CounselCIK: 0002019976
Associated companies
Transaction History
| CDNA | ▼ Sell | Tax Withholding | 997 | $66K | 10/1/2026 | View on chart |
| CDNA | ▼ Sell | Open Market | 2,188 | $101K | 8/5/2026 | View on chart |
| CDNA | ▼ Sell | Open Market | 500 | $23K | 8/5/2026 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 2,872 | $137K | 8/1/2026 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 997 | $29K | 7/1/2026 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 1,292 | $28K | 6/6/2026 | View on chart |
| CDNA | ▼ Sell | Open Market | 2,688 | $56K | 5/5/2026 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 2,873 | $62K | 5/1/2026 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 1,892 | $34K | 4/6/2026 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 3,987 | $71K | 4/1/2026 | View on chart |
| CDNA | ▼ Sell | Open Market | 4,441 | $91K | 2/3/2026 | View on chart |
| CDNA | ▲ Buy | Grant | 33,000 | $0 | 2/2/2026 | View on chart |
| CDNA | ▲ Buy | Grant | 4,342 | $0 | 2/2/2026 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 2,492 | $51K | 2/2/2026 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 2,970 | $61K | 2/2/2026 | View on chart |
| CDNA | ▼ Sell | Open Market | 7,007 | $134K | 12/4/2025 | View on chart |
| CDNA | ▼ Sell | Open Market | 286 | $6K | 12/4/2025 | View on chart |
| CDNA | ▼ Sell | Open Market | 2,688 | $42K | 11/7/2025 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 2,152 | $32K | 11/6/2025 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 2,872 | $42K | 11/1/2025 | View on chart |
| CDNA | ▼ Sell | Open Market | 2,688 | $34K | 8/5/2025 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 2,873 | $35K | 8/1/2025 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 276 | $5K | 7/7/2025 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 2,583 | $50K | 6/6/2025 | View on chart |
| CDNA | ▼ Sell | Open Market | 2,688 | $40K | 5/5/2025 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 2,873 | $43K | 5/1/2025 | View on chart |
| CDNA | ▼ Sell | Open Market | 924 | $16K | 4/7/2025 | View on chart |
| CDNA | ▲ Buy | Grant | 23,158 | $0 | 3/21/2025 | View on chart |
| CDNA | ▼ Sell | Open Market | 3,512 | $82K | 2/4/2025 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 2,048 | $48K | 2/3/2025 | View on chart |
| CDNA | ▼ Sell | Open Market | 1,917 | $50K | 12/4/2024 | View on chart |
| CDNA | ▼ Sell | Open Market | 365 | $9K | 11/25/2024 | View on chart |
| CDNA | ▼ Sell | Open Market | 858 | $21K | 11/25/2024 | View on chart |
| CDNA | ▼ Sell | Open Market | 3,656 | $79K | 11/18/2024 | View on chart |
| CDNA | ▼ Sell | Open Market | 807 | $18K | 11/18/2024 | View on chart |
| CDNA | ▼ Sell | Open Market | 1,071 | $24K | 11/18/2024 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 452 | $10K | 11/6/2024 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 1,905 | $43K | 11/1/2024 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 1,905 | $45K | 8/1/2024 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 183 | $3K | 7/8/2024 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 1,713 | $26K | 6/6/2024 | View on chart |
| CDNA | ▼ Sell | Tax Withholding | 1,905 | $17K | 5/1/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
CareDx shows high growth and fair‑value boost after reimbursement news
Recent coverage noted CareDx’s strong revenue growth and improving fundamentals. Analyst updates cited new reimbursement information and target revisions, leading to a modest fair‑value increase. The company’s performance appears to be gaining attention among investors.
CareDx shows high growth and fair‑value boost after reimbursement news. Recent coverage noted CareDx’s strong revenue growth and improving fundamentals. Analyst updates cited new reimbursement information and target revisions, leading to a modest fair‑value increase. The company’s performance appears to be gaining attention among investors.